{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:09:54Z","timestamp":1762459794114,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Millenium","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA051008"],"award-info":[{"award-number":["P30CA051008"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00280-019-03947-7","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T17:04:01Z","timestamp":1568912641000},"page":"1145-1151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6615-7076","authenticated-orcid":false,"given":"Filipa","family":"Lynce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongkun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel F.","family":"Petricoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula R.","family":"Pohlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Smaglo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimmy","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiwu R.","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepa S.","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Deeken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Pishvaian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,19]]},"reference":[{"key":"3947_CR1","volume-title":"Encyclopedia of cancer","author":"M Pishvaian","year":"2011","unstructured":"Pishvaian M, Marshall JL, He R, Wang D (2011) Epidermal growth factor inhibitors. In: Schwab M (ed) Encyclopedia of cancer. Springer, Berlin"},{"key":"3947_CR2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/cncr.22133","volume":"107","author":"J Marshall","year":"2006","unstructured":"Marshall J (2006) Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107:1207\u20131218","journal-title":"Cancer"},{"unstructured":"Tykerb [package insert]. Novartis, 2013","key":"3947_CR3"},{"issue":"4","key":"3947_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1634\/theoncologist.2011-0461","volume":"17","author":"FL Opdam","year":"2012","unstructured":"Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH (2012) Lapatinib for advanced or metastatic breast cancer. Oncologist 17(4):536\u2013542","journal-title":"Oncologist"},{"issue":"11","key":"3947_CR5","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1158\/1078-0432.CCR-15-2365","volume":"22","author":"KB Wisinski","year":"2016","unstructured":"Wisinski KB, Tevaarwek AJ, Burkard ME et al (2016) Phase I Study of an AKT inhibitor (MK-2206) combined with lapatinib in adults solid tumors followed by dose expansion in advanced HER2\u2009+\u2009breast cancer. Clin Cancer Res 22(11):2659\u20132667","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3947_CR6","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/cncr.29224","volume":"121","author":"JF Deeken","year":"2015","unstructured":"Deeken JF, Wang H, Subramaniam D et al (2015) A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies. Cancer 121(10):1645\u20131653","journal-title":"Cancer"},{"unstructured":"Velcade [package insert]. Millennium Pharmaceuticals, Inc., 2014","key":"3947_CR7"},{"key":"3947_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J Adams","year":"2004","unstructured":"Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4:349\u2013360","journal-title":"Nat Rev Cancer"},{"key":"3947_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1158\/0008-5472.CAN-06-2162","volume":"67","author":"JH Lorch","year":"2007","unstructured":"Lorch JH, Thomas TO, Schmoll HJ (2007) Bortezomib inhibits cell\u2013cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 67:727\u2013734","journal-title":"Cancer Res"},{"key":"3947_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/0008-5472.CAN-08-2938","volume":"69","author":"AH Kesarwala","year":"2009","unstructured":"Kesarwala AH, Samrakandi MM, Piwnica-Worms D (2009) Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation. Cancer Res 69:976\u2013983","journal-title":"Cancer Res"},{"key":"3947_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/1535-7163.MCT-06-0255","volume":"6","author":"J An","year":"2007","unstructured":"An J, Rettig MB (2007) Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 6:61\u201369","journal-title":"Mol Cancer Ther"},{"key":"3947_CR12","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/jcp.21444","volume":"216","author":"T Cascone","year":"2008","unstructured":"Cascone T, Morelli MP, Morgillo F et al (2008) Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. J Cell Physiol 216:698\u2013707","journal-title":"J Cell Physiol"},{"key":"3947_CR13","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1158\/1078-0432.CCR-07-4506","volume":"14","author":"CM Sloss","year":"2008","unstructured":"Sloss CM, Wang F, Liu R et al (2008) Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res 14:5116\u20135123","journal-title":"Clin Cancer Res"},{"key":"3947_CR14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2009.05.006","volume":"137","author":"J Luo","year":"2009","unstructured":"Luo J, Emanuele MJ, Li D et al (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835\u2013848","journal-title":"Cell"},{"key":"3947_CR15","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/sj.bjc.6605043","volume":"100","author":"AZ Dudek","year":"2009","unstructured":"Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ et al (2009) Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer 100:1379\u20131384","journal-title":"Br J Cancer"},{"key":"3947_CR16","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1200\/JCO.2009.22.7066","volume":"27","author":"R Lilenbaum","year":"2009","unstructured":"Lilenbaum R, Wang X, Gu L et al (2009) Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol 27:4487\u20134491","journal-title":"J Clin Oncol"},{"issue":"8","key":"3947_CR17","doi-asserted-by":"publisher","first-page":"e23780","DOI":"10.1371\/journal.pone.0023780","volume":"6","author":"C Mueller","year":"2011","unstructured":"Mueller C, Edmiston KH, Carpenter C et al (2011) One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One 6(8):e23780","journal-title":"PLoS One"},{"key":"3947_CR18","doi-asserted-by":"publisher","first-page":"R108","DOI":"10.1186\/bcr3575","volume":"15","author":"Y-J Chen","year":"2013","unstructured":"Chen Y-J, Yeh M-H, Yu M-C et al (2013) Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors. Breast Cancer Res 15:R108","journal-title":"Breast Cancer Res"},{"key":"3947_CR19","doi-asserted-by":"publisher","first-page":"19316","DOI":"10.18632\/oncotarget.2909","volume":"6","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Eaton AA, Gounder MM et al (2015) Predictors of early treatment discontinuation in patients enrolled on phase I oncology trials. Oncotarget 6:19316\u201319327","journal-title":"Oncotarget"},{"key":"3947_CR20","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.4161\/cc.19882","volume":"11","author":"S Akli","year":"2012","unstructured":"Akli S, Zhang XQ, Bondaruk J et al (2012) Low molecular weight cyclin E is associated with p27-resistant, high grade, high stage and invasive bladder cancer. Cell Cycle 11:1468\u20131476","journal-title":"Cell Cycle"},{"issue":"16","key":"3947_CR21","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.4161\/cc.25728","volume":"12","author":"L Tang","year":"2013","unstructured":"Tang L, Wang Y, Strom A et al (2013) Lapatinib induces p27(Kip1)-dependent G1 arrest through both transcriptional and post-translational mechanisms. Cell Cycle 12(16):2665\u20132674","journal-title":"Cell Cycle"},{"issue":"7","key":"3947_CR22","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/1535-7163.MCT-08-0168","volume":"7","author":"D Zhang","year":"2008","unstructured":"Zhang D, Pal A, Bornmann WG et al (2008) Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 7(7):1846\u20131850","journal-title":"Mol Cancer Ther"},{"key":"3947_CR23","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1074\/mcp.M112.019919","volume":"11","author":"K Imami","year":"2012","unstructured":"Imami K, Sugiyama N, Imamura H et al (2012) Temporal Profiling of lapatinib-suppressed phosphorylation signals in EGFR\/HER2 pathways. Mol Cell Proteomics 11:1741\u20131757","journal-title":"Mol Cell Proteomics"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03947-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03947-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03947-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T23:27:34Z","timestamp":1600385254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03947-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,19]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["3947"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03947-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2019,9,19]]},"assertion":[{"value":"21 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FL has received research grants from BMS, Pfizer, Genentech\/Roche, Immunomedics, Calithera, Chugai, Regeneron, Tesaro and Inivata; has participated in advisory boards (non-paid) with BMS, Jounce and AstraZeneca and travel expenses from BMS, Genentech and Jounce. EFP has a leadership role in Ceres Nanosciences and Perthera; has stock and other ownership interests in Avant Diagnostics, Ceres Nanosicences and Perthera; has consulting or advisory roles with Avant Diagnostics, AZGen, Ceres Nanosciences and Perthera; has received research funding from Abbvie, Ceres Nanosciences, GSK and Symphogen; has intellectual property rights in NIH Patents Licensing Fee Distribution\/Royalty and University assigned patent licensing fee\/royalty; has received travel expenses by Ceres Nanoscience and Perthera. PRP has intellectual property rights (United States Patents no. 8,486,413; no. 8,501,417; 9,023,362 and 9,745,377: Immunological Compositions as Cancer Biomarkers and\/or Therapeutics); has ownership interests in Immunonet BioSciences; has consulted for Heron, Personalized Cancer Therapy, PUMA, Pfizer, Oncoplex Dx, CARIS, Sirtex; has received financial support for educational programs (non-CME teaching) from ASCO, Dava Oncology, Roche; has received research grants to the institution from Immunonet BioSciences, Genentech\/Roche, Pfizer, Cascadian therapeutics\/Seattle Genetics, Fabre-Kramer, Advanced Cancer Therapeutics, Pieris. BS has received honoraria for speaking for TAIHO. DSS is an employee and has stock and other ownership interests in AZ; DSS was on speakers\u2019 bureau for AZ and Genentech until June 2019. JD has received research grants from Merck, BMS and Loxo Oncology and has outside income\/royalties from UpToDate. JM has been a speaker\/consultant and received honoraria from Genentech, Amgen, Celgene, Taiho, Bayer, Merck, Caris and Indivumed. MP has been a speaker\/consultant for AstraZeneca\/MedImmune, Caris Life Sciences, Celgene, Merrimack, Perthera, RenovoRx and Sirtex Medical; has received travel, accommodations and expenses Support from AstraZeneca\/MedImmune, Merck, Caris Life Sciences, Perthera and Sirtex Medical and has Stock interests in Perthera.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}